The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Jones T. Nauseef
No Relationships to Disclose
 
Paul J. Christos
No Relationships to Disclose
 
Charlene Thomas
Travel, Accommodations, Expenses - Inovio Pharmaceuticals; Nektar; Pfizer
 
Luke T. Nordquist
No Relationships to Disclose
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genzyme; Immunomedics; Incyte; Medscape; Merck; MSD; Pfizer; Roche; UroToday
 
Himisha Beltran
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Genzyme; GlaxoSmithKline; Janssen Oncology; Pfizer
Research Funding - Abbvie/Stemcentrx (Inst); Janssen (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Sabrina Guervil
No Relationships to Disclose
 
Giuseppe Galletti
No Relationships to Disclose
 
Paraskevi Giannakakou
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Patents, Royalties, Other Intellectual Property - International Patent Application DOCKET NO. 1676.083WO1 “Identifying Taxane Sensitivity in Prostate Cancer Patients” (Giannakakou, Plymate, co-inventors)
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics; Telix Pharmaceuticals
 
Ana M. Molina
Honoraria - ASCO
Consulting or Advisory Role - Eisai; Eisai; Eisai; Exelixis; Janssen